Treating coagulopathy in liver disease with plasma transfusions or recombinant factor VIIa: an evidence-based review.
In severe liver disease, poor synthetic function leads to characteristic deficiencies in numerous coagulation factors, and plasma transfusions are frequently administered to treat or prevent bleeding. This chapter reviews the available English-language randomized controlled trials, evidence-based practice guidelines, and observational studies relevant to establishing criteria for plasma transfusions in liver disease. The alternatives of pathogen-inactivated plasmas and recombinant factor VIIa were also reviewed from this perspective. In current guidelines, plasma transfusions are justified when haemostasis is needed for bleeding or invasive procedures, and the prothrombin time (PT) or partial thromboplastin time (PTT) is >1.5 times normal (mid-normal or, for PTT, sometimes upper limit). Conversion of the PT to the International Normalized Ratio has not been validated in liver disease. Solvent-detergent or methylene-blue treatments alter various clotting factors, which might affect efficacy in liver disease. Recombinant factor VIIa improves laboratory clotting measurements, but reduction of bleeding is less well established to date.
Ramsey
Glenn
G
Blood Bank, Northwestern Memorial Hospital, Northwestern University, Feinberg 7-301, 251 East Huron Street, Chicago, IL 60611, USA. g-ramsey@northwestern.edu
D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000209:etiology; D001803:Blood Transfusion; D015942:Factor VIIa / Q000627:therapeutic use*; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D015942:Factor VIIa